The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Borrower

B••••••• B••••••• B•••• S••

Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
Principal held
at least $143M
sum of BDC pieces, a lower bound
Fair value
$162M
96c on cost, debt pieces
Unfunded
n/a
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Oct 7, 2032
no dated debt inside 24 months
On the tape since
Mar 31, 2026
latest Jun 30, 2026
Events
1
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
FacilityHeldOn costPricingMaturityBDCs
first lien term loan first lienat least $143M96c//gwms.apollo.com/20260630#Euro Interbank Offered Rate+475 bpOct 7, 20321
Lenders
every BDC piece at the latest quarter end
BDCInstrumentPrincipalFair valueRate
A••••• D••• S•••••••• B••term loan first lien
Investment Type First Lien Secured D••• - Term Loan Interest Rate E+475, 0.00% Floor Matur
$143M$162M
96c
//gwms.apollo.com/20260630#Euro Interbank Offered Rate+475 bp
Through time
the borrower's pieces summed across BDCs, every quarter end
Quarter endBDCsPrincipal heldFair valueOn costPIK pieces
Jun 30, 20261$143M$162M96c0
Mar 31, 20261$143M$162M97c0
What changed
Every change including routine ones
Identity
Group key
BIOGARAN BASTILLEderivedthe codename stem after legal suffixes and deal words
Spellings
1 across 1 BDCderived
Industry
Pharmaceuticalsreportedas one filer wrote it